Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880308 · ClinicalTrials.gov registry record · Phase 1
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT00880308 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 103 participants.
The verdict
NCT00880308, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
Interventions
- DRUG LDE225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00880308
The ClinicalTrials.gov registry entry for NCT00880308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LDE225 is the first listed.
NCT00880308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00880308 about?
NCT00880308 is a clinical study titled "Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors". This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
What is the current status of trial NCT00880308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2009-03. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00880308?
The interventions under investigation include: LDE225 (DRUG).
Who is sponsoring clinical trial NCT00880308?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.